echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Today, it is reported that WuXi Junuo BCMA targeting CAR-T product has been approved for clinical use; magnetic thermal nanotechnology non-invasive treatment of Parkinson's...

    Today, it is reported that WuXi Junuo BCMA targeting CAR-T product has been approved for clinical use; magnetic thermal nanotechnology non-invasive treatment of Parkinson's...

    • Last Update: 2021-10-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Introduction: WuXi Giant Nuo BCMA targeted CAR-T product was approved for clinical use; the latest research shows that eating vegetables after eating farts is an important indicator of good health; magnetic thermal nanotechnology non-invasive treatment of Parkinson; Yinuo Pharmaceutical completed thousands Million USD in Series B financing.
    .
    .
    Biodiscovery will pay attention to the "medicine news" together with you, and explore the value of biotechnology!
    [New drug progress] 1.
    WuXi Juno BCMA targeted CAR-T product was approved for clinical use.
    On September 26, the official website of the Center for Drug Evaluation (CDE) of the National Medical Products Administration showed that WuXi Juno’s JWCAR129 (targeted BCMA) Chimeric Antigen Receptor T cells) were approved for clinical use in the treatment of relapsed/refractory multiple bone marrow.
    This is WuXi's second CAR-T therapy

    .

    WuXi Giant Nuo focuses on the development of innovative cell therapies in the Chinese market, bringing revolutionary new treatments to Chinese cancer patients.
    It has built a highly competitive cell therapy pipeline, and the company’s first CAR-T product has been It was approved for listing in early September

    .

    JWCAR129 is an autologous CAR-T product targeting BCMA.
    The clinical research indication approved for this drug is relapsed/refractory multiple myeloma

    .

    2.
    Corning Jereh updated the data of the Phase II clinical study of KN046 combined with chemotherapy for the first-line treatment of advanced pancreatic cancer.
    On September 27, Corning Jereh Biopharmaceuticals at the 24th National Conference on Clinical Oncology and the 2021 CSCO Academic Annual Meeting, Announced updated data of Phase II clinical study of KN046 combined with albumin paclitaxel/gemcitabine in the first-line treatment of advanced pancreatic ductal adenocarcinoma (PDAC)

    .

    KN046 is a PD-L1/CTLA-4 bispecific antibody independently developed by Corning Jereh.
    Its innovative design includes the fusion of CTLA-4 and PD-L1 single domain antibodies with different mechanisms; it can be targeted and enriched in PD- The tumor microenvironment with high expression of L1 and the elimination of Treg that inhibit tumor immunity

    .

    KN046-IST-04 is a phase II clinical study initiated by investigators in China.
    The results of the trial showed that in terms of safety, the incidence of KN046 treatment-related adverse events was 55.
    2%, and grade 3 and above accounted for 27.
    6%

    .

    Three cases (10.
    3%) had grade 3 or higher immune-related adverse reactions related to KN046, including skin rash and infusion reaction, autoimmune hepatitis, and elevated transaminases

    .

    The incidence of serious adverse events (SAE) related to KN046 was 3.
    4%, the incidence of adverse events (AE) related to KN046 leading to treatment termination was 6.
    9%, and no AEs leading to death occurred

    .

    [Basic scientific research] 1.
    Studies have shown that collagen loss is related to skin aging and "stem cell competition".
    The research team from Tokyo Medical University found through research that the reason why human skin can stay young and intact is mainly because of "stem cell competition".
    The key to competition lies in a type of collagen, namely COL17A1 protein

    .

    Studies have shown that the decline of COL17A1 collagen is a sign of skin aging
    .

    The researchers selected mouse tails as the research sample.
    The study found that in young mice, stem cells with low COL17A1 protein expression levels are more likely to fall off the basement membrane, and this competition maintains the integrity and youthfulness of the skin

    .

    With age, the level of COL17A1 collagen decreases, and there will be fewer and fewer stem cells with high COL17A1 protein expression.
    If they can’t compete with senescent cells, it will promote the replication and renewal of stem cells with low COL17A1 protein expression, leading to depletion of stem cells.
    The skin will age accordingly

    .

    When the expression of COL17A1 is restored, the competition of epidermal stem cells will resume, which alleviates skin aging to a certain extent
    .

    Therefore, related studies have shown that COL17A1 collagen promotes the "competition" of stem cells to maintain the integrity and health of the skin tissue
    .

    2.
    The latest research shows that love to fart after eating vegetables is an important indicator of good health.
    Recently, a study published in the journal "New Science" found that plant-based diets increase the risk of human farting, although it is embarrassing, but This phenomenon indicates that plant-based diet promotes the healthy growth of human intestinal bacteria

    .

    The researchers compared a plant-based Mediterranean diet with a Western diet containing a small amount of fruits and vegetables, and found that the plant-based diet subjects fart seven times as many times per day as the Western diet subjects
    .

    These data show that plant-based diets increase the chance of farting, which is actually the product of intestinal bacteria fermenting plant fiber
    .

    Fiber fermenting bacteria release short-chain fatty acids to ensure the health of the large intestine, and can also be absorbed into the blood, thereby reducing the body's cholesterol content and regulating the body's blood sugar level, further preventing people from suffering from heart disease, diabetes and other diseases
    .

    [Frontier technology] 1.
    The latest research to achieve dynamic labeling of dead neurons with fluorescent probes Parkinson, Alzheimer's disease, Huntington's disease, nutritional lateral sclerosis and other neurodegenerative diseases have typical neuronal progressive dysfunction and death

    .

    Although dyes have been used to observe neuronal death in vivo, the permeability of these dyes in tissues is different, so quantification is difficult
    .

    Recently, the Steven Finkbeiner research team of the Gladstone Institute in San Francisco modified the genetically encoded calcium ion indicator to develop a fluorescent probe GED1 that marks dead cells so that it can be located in the cytosol without affecting neurons.
    Activation responds, but it responds to changes in calcium ions caused by the time of neuron death, which can accurately mark dead neurons

    .

    2.
    Magnetic thermal nanotechnology non-invasive treatment of Parkinson's.
    Recently, the YasinTemel research team of Maastricht University Medical Center used non-invasive magnetic thermal deep brain stimulation technology to improve the motor function symptoms of Parkinson's model mice

    .

    Researchers used genetic engineering to wrap TRPV1 in a viral vector with a neuron promoter, so that neurons can express heat-activated ion channel proteins
    .

    After that, special magnetic nanoparticles are injected into the same area of ​​the brain.
    These nanoparticles are attached to the surface of the target neuron.
    When the mouse is in an alternating magnetic field, the magnetic field will quickly flip the magnetization of the nanoparticles, resulting in Thermal energy

    .

    The heat forces the temperature-sensitive ion channels to open and stimulate neurons
    .

    Through experiments, researchers can stimulate the subthalamic nucleus to stimulate the rotational motor function of mice.
    Subsequent immunofluorescence experiments found that the primary motor cortex neurons were activated, but the non-motor-related amygdala brain area did not appear to be this way.
    Activate

    .

    Next, in the two Parkinsonian mouse models, magnetic stimulation of the subthalamic nucleus can quickly and lastingly improve the motor dysfunction of the mice
    .

    The above experiments show that magnetic activation of the neural circuits in the subthalamic nucleus significantly improves dyskinesias and also activates motor cortical neurons, indicating that the effect of magnetic stimulation of the subthalamic nucleus will spread to the part of the brain associated with the subthalamic nucleus, and then exert it.
    Therapeutic effect

    .

    [Investment trend] 1.
    Yinuo Pharmaceuticals completed tens of millions of US dollars in Series B financing.
    Recently, Shanghai Yinuo Pharmaceuticals announced the completion of tens of millions of US dollars in Series B financing.
    This round of financing was led by the Shanghai Biomedical Fund, Shanlan Capital, Tiliang Capital, Huasai Zhikang and Shangshi Tianxin followed in the investment, and the old shareholder Zhang Ke led the additional investment

    .

    Founded in 2016, Yinuo Pharmaceutical has been focusing on the research and development of a class of new drugs.
    Through the understanding of complex disease mechanisms and key nodes of the signal network, guided by bioinformatics, it is committed to the development of "international first" drugs

    .

    At present, the company has built a product pipeline with autoimmune diseases and metabolic complications as the core, taking into account the combined drug strategy, and formed a "gradient advancement" product development strategy to ensure that at least one project per year enters the clinical application stage.

    .

    2.
    Hangzhou Jieyi Biotechnology Co.
    , Ltd.
    completed a strategic investment of hundreds of millions of yuan.
    Recently, Hangzhou Jieyi Biotechnology Co.
    , Ltd.
    announced the completion of a strategic investment of hundreds of millions of yuan

    .

    It is reported that this round of financing was jointly led by Alibaba and Huatai Zijin.
    Old shareholders such as Qianhai Fund of Funds and Proximity Venture Capital continued to increase their shares.
    Haoyue Capital served as the exclusive financial advisor for this round of financing

    .

    This round of financing is mainly used for new product research and development, registration and certification, and to further promote the national commercial application strategy
    .

    Jieyi Bio has the world's leading one-stop fully automated mNGS product solution, bringing the application scenarios of mNGS from third-party laboratories to the hospital, enabling mNGS detection to be zero distance from patients, and changing the business model of mNGS
    .

    In addition, the company first launched a quantitative mNGS detection project in the country to solve the problem that traditional mNGS can only be targeted but not quantified, and achieve targeted detection of human-source and pathogenic nucleic acids
    .

    htm?id=1013 Selected onlookers in the past Nature blockbuster: This malignant tumor with the highest lethality rate may usher in the era of precision treatment.
    The hot text has generated hundreds of billions of revenue in 6 months.
    Why is mRNA so "god"?
    Hot article latest! The "Patient Zero" of the new crown in the United States has a high probability of appearing in the hot article Cell sub-news around September 2019: Create a miracle of life again! Scientists use pluripotent stem cells to successfully cultivate artificial sperm, which can produce healthy offspring.
    AJCN: To live longer, eat beans often!
    Long-term consumption of soybean diet can make the brain "more agile".
    Medical immunotherapy | Biosimilars | Vaccines | Drug resistance | Drug targets | Healthy life | Pharmaceutical news | Drug inventory | Pharmaceutical technology | Basic research on side effects of drugs / Translational medicine leukemia | Lung Cancer | Gastric Cancer | Colorectal Cancer | Liver Cancer | Breast Cancer | Pancreatic Cancer | Cardiovascular Diseases | Neurodegenerative Diseases | Intestinal Microbial Medical Devices / Biotechnology In Vitro Diagnosis | Medical Devices | Cell Sequencing | Gene Editing | Assisted Reproduction | Artificial Intelligence | Precision Medicine Policy Anti-cancer Drugs | 4+7 Quantity Procurement | Consumables | Record-filing System | Registrant System | Healthy China | New Edition Essential Medicine Catalog | AI Medical Devices | Telemedicine | Same-share non-equity market/capital IPO | Financing | Cooperation | Funds | Hong Kong Stock Exchange | Science and Technology Innovation Board | Growth Enterprise Market |
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.